Foreign Pharmaceutical & Device Companies Deepen Engagement in China: Local Innovation & Increased Investment Highlight CIIE
The recent China International Import Expo (CIIE) underscored a growing trend: foreign pharmaceutical and medical device companies are increasingly focusing on localized innovation and expanding their investment within China. This shift aims to better serve the Chinese market,accelerate access to new therapies,and contribute to the growth of the nation’s healthcare industry.
A key theme highlighted at the CIIE was the commitment to utilizing the event as a platform for introducing breakthrough therapies in critical areas like oncology, immunity, neuroscience, and cardiopulmonary diseases. The goal is to streamline the process of drug registration and launch, effectively bridging the gap between research & progress and patient access, ultimately meeting the evolving health needs of the Chinese population.
Fosun Pharma exemplified this trend, demonstrating a transition from simply “introducing” foreign technologies to actively “localizing” them. The company showcased the Marie vertical particle therapy system, a compact alternative to traditional radiotherapy.Moreover, their JediVision pulmonary nodule AI-AR navigation system, combining domestically developed software and hardware, is already in clinical use at leading hospitals nationwide.
Fosun Pharma is also making notable strides in cell therapy. yikaida® (Akilenza Injection), China’s first CAR-T product, has successfully treated over 1,000 lymphoma patients, with accessibility improved through collaborations with medical and commercial insurance providers. The company announced in september 2025, the State Food and Drug Administration accepted the drug registration request for their second CAR-T product, brigiolenza Injection (FKC889), intended for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Beyond therapies, Fosun Pharma is actively localizing manufacturing. The da Vinci xi surgical robot is now being domestically produced, with expectations that over 70% of units sold in China by the end of 2025 will be manufactured locally. The opening of Intuitive Fosun’s headquarters industrial base in Pudong, Shanghai, represents Intuitive medical’s largest integrated R&D and production center in the Asia-Pacific region, signifying a move ”from exhibitor to investor.”
(Source: Guangzhou Daily New Flower City)
Disclaimer: Oriental Fortune publishes this content to disseminate more details. It has nothing to do with the position of this site and does not constitute investment advice. Operate accordingly at your own risk.
